ALK and non-small cell lung carcinoma: Therapeutic agents such as afatinib, osimertinib, gefitinib and erlotinib have shown promising results in patients with NSCLC who have driver mutations such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) [19].